

FINANCIAL RESULTS

OF

**ACCRETION PHARMACEUTICALS LIMITED
(CIN: U21004GJ2023PLC146545)**

FOR THE HALF YEAR ENDED 31ST MARCH, 2025

COMPANY INFORMATION

BOARD OF DIRECTORS

Harshad Nanubhai Rathod	Promoter Director
Hardik Mukundbhai Prajapati	Promoter Director
Mayur Popatlal Sojitra	Promoter Director
Vivek Ashok Kumar Patel	Promoter Director
Grishma A Shewale	Independent Director
Chand Rameshbhai Kanabar	Additional Independent Director
Nishtha Harivanshi Pamnani	Additional Independent Director

STATUTORY AUDITOR

M/s. VSSB & Associates

CHARTERED ACCOUNTANTS

A/912, 9th Floor, Ratnaakar Nine Square, Opp. Keshavbaug Party Plot,
Vastrapur, Ahmedabad - 380015, Gujarat, India

BANKER

Indian Bank

Paldi Branch

REGISTERED OFFICE

ACCRETION PHARMACEUTICALS LIMITED

CIN: U21004GJ2023PLC146545

PAN: AAZCA7550K

Reg. Office: 29 Xcelon Ind Park 1, B/h Intas Pharmaceuticals,
Vasna Chacharvadi, Sanand, Ahmedabad-382213, Gujarat, India

E-Mail: info@accretion.co.in

INDEPENDENT AUDITOR'S REPORT

Independent Auditor's Report on Standalone Half Yealy Financial Results and year to date result of Accretion Pharmaceuticals Limited ("the Company") pursuant to the requirements of Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015, as amended.

TO THE BOARD OF DIRECTORS of ACCRETION PHARMACEUTICALS LIMITED

Opinion

We have audited the accompanying statement of half yearly and year to date standalone financial results of Accretion Pharmaceuticals Limited (hereinafter referred to as the "Company") for the year ended 31 March 2025, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("The Listing Regulations").

In our opinion, to the best of our information, according to the explanations given to us, the aforesaid Standalone Financial Results for the year ended 31st March 2025:

- are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable in the applicable Accounting Standards Prescribed under section 133 of the Companies Act, 2013 ("Act"), as amended, and other accounting principles generally accepted in India under of the net profit and other financial information for the year ended 31 March 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in the Auditor's Responsibilities section below. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("the ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial results for the year ended 31st March 2025 under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.



Responsibilities of the Management and Those Charged with Governance for this Statement:

This accompanying Statement, which includes the Standalone Financial Results for the year ended 31st March 2025 is the responsibility of the Company's Board of Directors and has been approved by them for the issuance. This responsibility includes the preparation and presentation of the Standalone Financial Results for the half yearly and year ended 31st March, 2025 that give a true and fair view of the net profit and other financial information in accordance with the recognition and measurement principles laid down in the applicable Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulations 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the accompanying Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Standalone Financial Results for the year ended 31st March, 2025:

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results for the year ended 31st March 2025 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Annual Standalone Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We are also:



- Identify and assess the risks of material misstatement of the Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Standalone Financial Results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the standalone financial results of the company to express an opinion on the standalone financial results.

Materiality is the magnitude of misstatements in the Standalone financial results that, individually or in aggregate, makes it probable that economic decisions of a reasonably knowledgeable users of the standalone financial results may be influenced. We consider Quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



Other Matter

1. Company is listed on NSE Emerge (SME) stock exchange as on 21/05/2025, and this is the first Financial Result of the Company.
2. The accompanying Statement includes the results for the half year ended 31st March, 2025 being the balancing figure between audited figures in respect of the full financial year and year to date figures up to the half year of the current financial year. Our opinion on the Audit of the Standalone Financial Results for the year ended 31st March 2025 is not modified in respect of this matter.

Date 10/06/2025

Place Ahmedabad



For, V S S B & Associates

Chartered Accountants.

Firm Reg. No.121356W

Vishves A. Shah
(Partner)

Membership No. 109944

UDIN: 25109944BMGPMN6301

ACCRETION PHARMACEUTICALS LIMITED (CIN: U21004G12023PLC146545) Regd. Office :- 29 Xcelon Ind Park 1, B/7, Intas Pharmaceuticals, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat, India, 382213 Audited Statement of Standalone Financial Result for the half year ended March 31, 2025					
(Amount in Lakhs)					
Particulars	Half Year Ended			Year Ended	
	31-03-2025	30-09-2024	31-03-2024	31-03-2025	31-03-2024
	(Audited)	(Unaudited)	(Audited) (See Note 4)	(Audited)	(Audited) (See Note 4)
I Revenue from Operations	3881.20	1856.42	1335.25	5737.62	1335.25
II Other Income	7.91	1.53	5.47	9.44	5.47
III Total Income (I + II)	3889.11	1857.95	1340.71	5747.06	1340.71
IV Expenses					
Cost of Material Consumed	2921.91	1449.10	1516.78	4371.01	1516.78
Purchases	0.00	0.00	0.00	0.00	0.00
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(129.06)	(250.98)	(580.19)	(380.04)	(580.19)
Employee Benefits Expenses	213.49	154.00	90.08	367.49	90.08
Finance Costs	74.27	69.42	39.92	143.69	39.92
Depreciation and Amortization Expense	40.75	36.70	22.35	77.45	22.35
Other Expenses	120.73	70.35	52.27	191.08	52.27
Total Expense	3242.09	1528.59	1141.21	4770.68	1141.21
V Profit before Exceptional and Extraordinary Items and Tax (III-IV)	647.02	329.36	199.50	976.38	199.50
VI Exceptional Items	0.00	0.00	0.00	0.00	0.00
VII Profit before Extraordinary Items and Tax (V-VI)	647.02	329.36	199.50	976.38	199.50
VIII Extraordinary Items	0.00	0.00	0.00	0.00	0.00
IX Profit Before Tax (VII-VIII)	647.02	329.36	199.50	976.38	199.50
X Tax Expense:					
(a) Current Tax	177.04	82.89	50.08	259.93	50.08
(b) Deferred Tax	19.32	0.00	0.14	19.32	0.14
(c) MAT Credit Entitlement	0.00	0.00	0.00	0.00	0.00
(d) Income Tax of Previous Year	17.78	0.00	0.00	17.78	0.00
Total Tax Expense	214.14	82.89	50.21	297.03	50.21
XI Profit for the Period from Continuing Operations (IX - X)	432.89	246.47	149.29	679.35	149.29
XII Profit/(Loss) for the Period from Discontinuing Operations	0.00	0.00	0.00	0.00	0.00
XIII Tax Expense of Discontinuing Operations	0.00	0.00	0.00	0.00	0.00
XIV Profit/(Loss) from Discontinuing Operations (After Tax) (XII-XIII)	0.00	0.00	0.00	0.00	0.00
XV Profit for the Period (XI + XIV)	432.89	246.47	149.29	679.35	149.29
XVI Paid up Share Capital (Face Value Rs. 10/Share)	817.00	817.00	400.00	817.00	400.00
XVII Reserve excluding Revaluation Reserves	-	-	-	711.65	149.29
XVIII Earnings Per Equity Share:					
Basic (Rs.) & Diluted (Rs.) (See Note 8)	5.30	3.14	1.96	8.48	1.96
Notes: 1 The above Audited financial results were reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 10/06/2025. 2 The previous periods figures have been regrouped wherever necessary. 3 The Statutory auditors of the company have carried out an Audit and issued "Independent Auditor's report" of the above results as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015. 4 The Company has been incorporated as on 29th November, 2023 by conversion of Partnership Firm. Hence, Previous year's Audited figures of the Company consist of period between 29/11/2023 to 31/03/2024. 5 The Company is mainly engaged in the business of manufacture, process, trade, sale, purchase, import, export, assemble, distribute, formulate, develop, consult, test and deal in all kind of Drugs, Pharmaceuticals products and related products thereto and which is considered as only reportable primary business segment as per Accounting Standard "Segment Reporting" (AS - 17). As such, no separate disclosure for Segment Reporting is made. 6 The figures for the half year ended 31st March, 2025 are the balancing figures between the audited figures in respect of full financial year and the year-to-date figures up to the first half year of the financial year. 7 The company had made an initial public offering (IPO) of 29,46,000 equity shares of face value of Rs. 10 each fully paid up for cash at a price of Rs. 101 per equity shares (including share premium of Rs. 91 per equity share) aggregating to Rs. 29,75,46,000/- The equity shares of the company got listed on NSE Emerge Platform on 21st May, 2025. 8 Earning per share is not retrospectively effected due to Fresh issue of equity as it is considered as Non-Adjusting event as per AS 4 "Contingencies and Events Occurring After the Balance Sheet Date".					
<div><div>Place: Ahmedabad Date : 10/06/2025</div><div><div>For and on Behalf of the Board of, ACCRETION PHARMACEUTICALS LIMITED  Vivek Ashok Kumar Patel (Managing Director) CIN: 09130357</div></div></div>					

ACCRETION PHARMACEUTICALS LIMITED

(CIN: U21004GJ2023PLC146545)

Regd. Office :- 29 Xcelon Ind Park 1, B/h, Intas Pharmaceuticals, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat, India, 382213

Audited Statement of Assets & Liabilities as at 31st March, 2025

(Amount in Lakhs)



	Particulars	Audited	Audited
		AS AT 31.03.2025	AS AT 31.03.2024
I	Equity & Liabilities		
	1. Shareholders' funds		
	(a) Share Capital	817.00	400.00
	(b) Reserves and Surplus	711.65	149.29
	(c) Money received against share warrants	0.00	0.00
	2. Share application money pending allotment	0.00	0.00
		1528.65	549.29
	3. Non - Current Liabilities		
	(a) Long - Term Borrowings	116.76	691.07
	(b) Deferred Tax Liabilities (Net)	19.45	0.14
	(c) Other Long - Term Liabilities	0.00	0.00
	(d) Long - Term Provisions	0.00	0.00
	4. Current Liabilities		
	(a) Short - Term Borrowings	1293.58	656.71
	(b) Trade Payables		
	Micro and Small Enterprises	183.90	163.95
	Other than Micro and Small Enterprises	574.72	493.80
	(c) Other Current Liabilities	4.47	3.00
	(d) Short - Term Provisions	265.90	128.95
		2458.79	2137.61
	Total	3987.44	2686.90
II	Assets		
	1. Non - Current Assets		
	(a) Property, Plant & Equipment & Intangible Assets		
	(i) Property, Plant & Equipment	609.09	525.46
	(ii) Intangible Assets	0.00	0.00
	(iii) Capital Work-in-Progress	0.00	0.00
	(iv) Intangible Assets under Development	0.00	0.00
	(b) Non - Current Investments	0.00	0.00
	(c) Long - Term Loans and Advances	7.56	0.00
	(d) Other Non - Current Assets	16.08	13.38
	(d) Deferred Tax Assets (Net)	0.00	0.00
		632.73	538.85
	2. Current Assets		
	(a) Inventories	2060.97	1447.58
	(b) Trade Receivables	1166.11	580.44
	(c) Cash and Cash equivalents	5.08	9.16
	(d) Short - Term Loans and Advances	110.36	105.42
	(e) Other Current Assets	12.18	5.45
		3354.71	2148.06
	Total	3987.44	2686.90

Place : Ahmedabad
Date : 10/06/2025



For & on behalf of the Board,
ACCRETION PHARMACEUTICALS LIMITED

(Signature)
Vivek Ashok Kumar Patel
(Managing Director)
DIN : 09130357

ACCRETION PHARMACEUTICALS LIMITED				
(CIN: U21004GJ2023PLC146545)				
Regd. Office :- 29 Xcelon Ind Park 1, B/h, Intas Pharmaceuticals, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat, India, 382213				
AUDITED CASH FLOW STATEMENT FOR THE HALF YEAR ENDED MARCH 31, 2025				
Particulars	Period ended		(Amount in Lakhs)	
	31th March, 2025		Year ended	
	Rs.		31st March, 2024	
	Rs.		Rs.	
CASH FLOW FROM OPERATING ACTIVITIES				
Net Profit before Tax for the year		976.38		199.50
Adjustments for :				
Transferred from reserve	0.00		0.00	
Interest Expense	143.69		39.92	
Depreciation	77.45		22.35	
		221.14		62.26
Operating Profit before Working Capital change		1197.53		261.76
Adjustments for :				
Decrease/(Increase) in Receivables	(585.67)		(704.69)	
Decrease/(Increase) in Inventories	(613.38)		(1447.58)	
Decrease/(Increase) in Short Term Loans & Advances	(4.95)		0.00	
Decrease/(Increase) in Other Current Assets	(6.73)		0.00	
Increase/(Decrease) in Short Term Borrowing	636.87		0.00	
Increase/(Decrease) in Payables	100.87		660.75	
Increase/(Decrease) in Current Liabilities	1.47		0.00	
Other Non Current Asset	(2.70)		0.00	
Increase/(Decrease) in Provisions	45.01	(429.21)	0.00	(1491.52)
Cash Generated From Operations		768.32		(1229.76)
Income Tax		185.77		78.87
NET CASH FROM OPERATING ACTIVITIES Total (A)		582.55		(1150.89)
CASH FLOW FROM INVESTING ACTIVITIES				
Non Current Investment			0.00	
Purchase Of Fixed Asset	(161.08)		(547.81)	
NET CASH USED IN INVESTING ACTIVITIES Total (B)		(161.08)		(547.81)
CASH FLOW FROM FINANCING ACTIVITIES				
Long Term Borrowing	(574.31)		1347.78	
Proceeds from share issued including share application money	300.00		400.00	
Long Term Loans & Advances	(7.56)		0.00	
Interest Expenses	(143.69)		(39.92)	
NET CASH FROM FINANCING ACTIVITIES Total (C)		(425.56)		1707.86
Net Increase/(Decrease) in Cash and Cash Equivalents Total (A+B+C)		(4.08)		9.16
Cash and Cash Equivalents -- Opening Balance		9.16		0.00
Cash and Cash Equivalents -- Closing Balance		5.08		9.16
		0.00		0.00
Note: Previous year's figures have been regrouped/rearranged wherever considered necessary.				
<div> <div>Place: Ahmedabad Date : 10/06/2025</div> <div> <div>For & on behalf of the Board, ACCRETION PHARMACEUTICALS LIMITED</div> <div>  <div>  <div> Vivek Ashok Kumar Patel (Managing Director) DIN: 09130357 </div> </div> </div> </div> </div>				